Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Prospective Study Assessing the Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir (G/P) in Patients with Chronic Hepatitis C Virus Infection within the German Hepatitis C-Registry (DHC-R)

Trial Profile

A Multicenter, Prospective Study Assessing the Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir (G/P) in Patients with Chronic Hepatitis C Virus Infection within the German Hepatitis C-Registry (DHC-R)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs Glecaprevir/pibrentasvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Nov 2018 Results of a retrospective analysis assessing Drug-Drug Interaction Potential of Glecaprevir/ Pibrentasvir (n=19,042) presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
    • 07 Oct 2018 Results presented at the IDWeek 2018
    • 10 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top